Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNC210 for Acute Treatment of Social Anxiety Disorder
NCT06510504Phase 3Completed
- Sponsor
- Neuphoria Therapeutics Inc.
- Start
- Aug 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of soclenicant in Social Anxiety Disorder (SAD), sponsored by Neuphoria Therapeutics Inc.. Started Aug 2024; status: completed.
02
Drugs
soclenicant
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT06510504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06510504.